Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 1,602 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Skin Patch Clear all

Conditions: Nicotine Dependence
Interventions: Nicotine patch - transdermal, placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anorexia Nervosa
Interventions: Testosterone, Actonel (risedronate), Placebo Actonel (risedronate), Placebo testosterone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Smoking, Smoking Cessation
Interventions: Nicotine Replacement Product; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Veterans, Tobacco Use Disorder, Cigarette Smoking, Tobacco Dependence
Interventions: Motivation-Phase Varenicline, Motivation-Phase Nicotine Mini-Lozenge, Cessation-Phase Combination Nicotine Replacement Therapy (NRT), Cessation-Phase Varenicline, Motivation-Phase Counseling, Cessation-Phase Counseling; Drug · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: San Diego, California • Minneapolis, Minnesota • Durham, North Carolina + 1 more

Conditions: Smoking Cessation
Interventions: Nicotine patch, in-person counseling and quitline counseling, Preparation Nicotine Mini-Lozenges, Combination NRT (nicotine patch + nicotine mini-lozenges), Intensive In-Person Cessation Counseling, Extended Maintenance Counseling Calls, Automated Adherence Calls; Drug · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Onychomycosis
Interventions: HTU-520 Patch, Placebo Patch; Drug · Other
Lead sponsor: Hisamitsu Pharmaceutical Co., Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 37
States / cities: Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 30 more

Conditions: Low Back Pain
Interventions: lidocaine 5% patch, standard therapy, Non-medicated patch; Drug
Lead sponsor: Cook County Health; Government
Eligibility: 24 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Postoperative Edema and Pain
Interventions: ActiPatch(TM), Placebo; Device
Lead sponsor: Tufts University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atrial Fibrillation (AF), Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Interventions: Not listed
Lead sponsor: Tina Baykaner; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Duarte, California • San Diego, California • Stanford, California

Conditions: Alzheimer's Disease
Interventions: Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 23
States / cities: Sun City, Arizona • Costa Mesa, California • Fresno, California + 20 more

Conditions: Chronic Low Back Pain
Interventions: Bupivacaine TTS (Bupivacaine Patch), Placebo patch; Drug
Lead sponsor: Durect; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: Tempe, Arizona • La Mesa, California • Torrance, California + 18 more

Conditions: Healthy
Interventions: Vacuum-Assisted Microneedle Device; Device
Lead sponsor: Sharon Pitteri; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Stanford, California

Conditions: Sudden Cardiac Arrest
Interventions: Jewel Patch Wearable Cardioverter Defibrillator (P-WCD); Device
Lead sponsor: Element Science, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 30
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Hartford, Connecticut + 25 more

Conditions: Alzheimer Disease
Interventions: Donepezil TDS Version A, Donepezil TDS Version B, Aricept, Donepezil TDS Version D, Donepezil TDS Version E; Drug
Lead sponsor: Corium, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Premature Ovarian Failure
Interventions: Estradiol/Medroxyprogesterone acetate; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers
Interventions: Buprenorphine transdermal patch, Matching placebo transdermal patch, Avelox (moxifloxacin hydrochloride) tablet; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hematologic Malignancy
Interventions: TempTraq, VitalTraq; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Amblyopia
Interventions: Atropine, Eye Patch; Drug · Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: Up to 6 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Restless Legs Syndrome
Interventions: buprenorphine transdermal delivery system (BTDS), Placebo for BTDS patch; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 25 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alcohol Drinking
Interventions: 21mg transdermal nicotine patch (Nicoderm CQ), 1mg nicotine nasal spray, placebo nasal spray; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: lidocaine, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 159
States / cities: Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 95 more

Conditions: Smoking Behaviors
Interventions: Aim 1: Online survey, Eye Tracking Activity, Eye tracking survey, Online Experimental Marketplace (ETM), Aim 3 survey, Cognitive Interviews, Supplemental Aim 1 Interviews; Other · Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 16 Years to 28 Years
Enrollment: 658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Restless Legs Syndrome
Interventions: Rotigotine; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 279 participants
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: RTP, North Carolina

Conditions: Controlling Mild to Moderate Bleeding During Surgery
Interventions: EVARREST® Fibrin Sealant Patch; Biological
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 28 Days to 17 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Birmingham, Alabama • New York, New York

Search by objective public record fields.

Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging

Bone Loss in Women With Anorexia Nervosa

Treating Caregivers Who Smoke at AFCH

Varenicline for Smoking Reduction in Veterans Not Ready To Quit

A Comparative Effectiveness RCT of Optimized Cessation Treatments

Safety & Efficacy Study of HTU-520 in the Treatment of Distal Subungual Onychomycosis of the Toenail

Adjunctive 5% Lidocaine Patches for Acute Non-radicular Low Back Pain in Emergency Department Patients

Third Molar Extraction and Pulsed Electromagnetic FieldTherapy

Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy

Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease

Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain

Study of Dermal Interstitial Fluid Collection With a Vacuum-Assisted Microneedle Device

The Jewel IDE Study

A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®

Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

VitalTraq for the Detection of CRS

Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia

Butrans for Treatment of Restless Legs Syndrome

Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy

Lidocaine Patch in Treating Cancer Patients With Neuropathic Pain After Surgery

C-FLASH (Cigarillo Flavor and Abuse Liability, Attention, and Substitution in youtH)

An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome

The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study